AtriCure, a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, and systems for the exclusion of the left atrial appendage, has announced that Robert S White has been appointed to the company’s board of directors, effective immediately.
White is a veteran in the medical technology industry with over 25 years of experience in commercial expansion, operations and sales. He is currently president and CEO of TYRX, a privately-held company, which commercialises innovative, implantable combination drug and device products focused on infection control, including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices. Prior to joining TYRX, White held several positions with Medtronic. White served as president of Medtronic Kyphon following its US$3.9 billion acquisition of the spinal treatment business.
During his time with Medtronic, White also served as president of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as vice president of USA. Sales and Global Marketing. Earlier in his career, White held positions with General Electric Company and Eli Lilly and Company among others.
“Bob has significant leadership experience spanning operations, business development and sales and marketing within the medical device industry, and I believe he will bring significant value to AtriCure and its board of directors,” said Michael Carrel, president and CEO of AtriCure. “It was immediately clear that Bob exceeded our collective criteria for a board member as he is a seasoned executive with extensive experience growing companies commercially. His experience managing and growing several hundred million dollar divisions within Medtronic, and as the current CEO of TYRX, will be incredibly valuable as we seek to further penetrate the atrial fibrillation market. We are thrilled to have him on board.”
“I am pleased to be joining AtriCure, a company at its inflection point in terms of growth and of making great progress in the treatment of atrial fibrillation,” said White. “I look forward to working with the board and the team at AtriCure to help execute on a solid strategy to expand commercialisation and further develop the current and future pipeline.”